Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIVCD8+ cytotoxic T-cell epitopes

被引:49
作者
Woodberry, T
Gardner, J
Mateo, L
Eisen, D
Medveczky, J
Ramshaw, IA
Thomson, SA
French, RA
Elliot, SL
Firat, H
Lemonnier, FA
Suhrbier, A
机构
[1] Queensland Inst Med Res, Australian Ctr Int & Trop Hlth & Nutr, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia
[2] Royal Brisbane Hosp, Infect Dis Unit, Brisbane, Qld, Australia
[3] Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Canberra, ACT 2601, Australia
[4] Australian Natl Univ, Paediat Res Labs, Randwick, NSW, Australia
[5] Inst Pasteur, Dept SIDA Retrovirus, Unite Immunite Cellulaire Antivirale, Paris, France
关键词
D O I
10.1128/JVI.73.7.5320-5325.1999
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Compelling evidence now suggests that alpha beta CD8 cytotoxic T lymphocytes (CTL) have an important role in preventing human immunodeficiency virus (HIV) infection and/or slowing progression to AIDS. Here, we describe an HIV type 1 CTL polyepitope, or polytope, vaccine comprising seven contigous minimal HLA A2-restricted CDS CTL epitopes conjoined in a single artificial construct. Epitope-specific CTL lines derived from HIV-infected individuals were able to recognize every epitope within the construct, and HLA A2-transgenic mice immunized with a recombinant virus vaccine coding for the HIV polytope also generated CTL specific for different epitopes, Each epitope in the polytope construct was therefore processed and presented, illustrating the feasibility of the polytope approach for HIV vaccine design. By simultaneously inducing C-TL specific for different epitopes, an HIV polytope vaccine might generate activity against multiple challenge isolates and/or preempt the formation of CTL escape mutants.
引用
收藏
页码:5320 / 5325
页数:6
相关论文
共 46 条
[1]   A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and T-h epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen [J].
An, LL ;
Whitton, JL .
JOURNAL OF VIROLOGY, 1997, 71 (03) :2292-2302
[2]  
BRAND VM, 1998, EUR J IMMUNOL, V28, P625
[3]   Who is right? Or, how to judge the disagreement about HLA restriction of Nef peptides - Comment [J].
Brander, C ;
Walker, BD ;
Korber, B .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (11) :923-924
[4]   Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection [J].
Brander, C ;
Hartman, KE ;
Trocha, AK ;
Jones, NG ;
Johnson, RP ;
Korber, B ;
Wentworth, P ;
Buchbinder, SP ;
Wolinsky, S ;
Walker, BD ;
Kalams, SA .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) :2559-2566
[5]  
BRANDER C, 1998, SYSTEMATIC IDENTIFIC
[6]  
CLEMENTSMANN ML, 1998, NIAID AIDS VACCINE E, V177, P1230
[7]   HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes [J].
Collins, KL ;
Chen, BK ;
Kalams, SA ;
Walker, BD ;
Baltimore, D .
NATURE, 1998, 391 (6665) :397-401
[8]   A GENERAL-METHOD FOR THE CONSTRUCTION OF RECOMBINANT VACCINIA VIRUSES EXPRESSING MULTIPLE FOREIGN GENES [J].
COUPAR, BEH ;
ANDREW, ME ;
BOYLE, DB .
GENE, 1988, 68 (01) :1-10
[9]  
DUPUIS M, 1995, J IMMUNOL, V155, P2232
[10]   Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy [J].
Ferrari, G ;
Berend, C ;
Ottinger, J ;
Dodge, R ;
Bartlett, J ;
Toso, J ;
Moody, D ;
Tartaglia, J ;
Cox, WI ;
Paoletti, E ;
Weinhold, KJ .
BLOOD, 1997, 90 (06) :2406-2416